Sun Pharmaceutical Industries
Sun Pharmaceutical Industries Share Price Chart
Sun Pharmaceutical Industries last traded at ₹1,760.00 (2026-10-13). Over the past month the stock moved -5.6%, three months the stock moved -4.4%, year the stock moved +6.3%. Its closing range over 52 weeks is ₹1,610.10 – ₹1,956.00, with the latest close 10.0% below the high.
Closing prices up to 2026-10-13.
About Sun Pharmaceutical Industries
Sun Pharmaceutical Industries Ltd is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulations and Active Pharma Ingredients (APIs). The company and its subsidiaries has various manufacturing facilities spread across the world with trading and other incidental and related activities extending to global market.[1] It is the largest pharmaceutical company in India.[2]
Product Offerings:[1][2] The company produces a range of generic and specialty medications for chronic and acute conditions. Its product portfolio includes generics, branded generics, specialty pharmaceuticals, advanced technology-based products, antiretrovirals, active pharmaceutical ingredients (APIs), and intermediates. It offers medications in multiple dosage forms, such as injectables, sprays, ointments, creams, liquids, tablets, and capsules. The company offers 27 products in the global specialty market, with a strategic focus on dermatology, ophthalmology, and onco-dermatology segments.[3]
Fundamentals
Quarterly Results
In the latest quarter (Jun 2026), Sun Pharmaceutical Industries reported sales of ₹15,300.00 crore (+10.5%) and net profit of ₹2,901.00 crore (+26.5%), compared with the same quarter last year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Jun 2026 | 15,300 | 4,418 | 29.00 | 2,901 | 12.06 |
| Mar 2026 | 14,612 | 3,954 | 27.00 | 2,710 | 11.31 |
| Dec 2025 | 15,521 | 4,948 | 32.00 | 3,381 | 14.04 |
| Sep 2025 | 14,478 | 4,527 | 31.00 | 3,125 | 13.00 |
| Jun 2025 | 13,851 | 4,302 | 31.00 | 2,293 | 9.50 |
| Mar 2025 | 12,959 | 3,716 | 29.00 | 2,154 | 8.96 |
| Dec 2024 | 13,675 | 4,009 | 29.00 | 2,913 | 12.10 |
| Sep 2024 | 13,291 | 3,939 | 30.00 | 3,037 | 12.67 |
| Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales growth | +9.0% | +10.5% | +8.1% | +9.5% | +8.9% | +13.5% | +12.8% | +10.5% |
| Operating profit growth | +23.9% | +15.3% | +22.4% | +19.2% | +14.9% | +23.4% | +6.4% | +2.7% |
| Net profit growth | +27.3% | +13.7% | -19.0% | -19.9% | +2.9% | +16.1% | +25.8% | +26.5% |
| EPS growth | +28.0% | +15.0% | -19.0% | -19.6% | +2.6% | +16.0% | +26.2% | +26.9% |
| OPM % | 30.0% | 29.0% | 29.0% | 31.0% | 31.0% | 32.0% | 27.0% | 29.0% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
Annual Financials
In the latest year (Mar 2026), Sun Pharmaceutical Industries reported sales of ₹58,462.00 crore (+11.2%) and net profit of ₹11,509.00 crore (+5.0%), compared with the previous year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Mar 2026 | 58,462 | 17,731 | 30.00 | 11,509 | 47.84 |
| Mar 2025 | 52,578 | 15,114 | 29.00 | 10,965 | 45.55 |
| Mar 2024 | 48,497 | 13,018 | 27.00 | 9,610 | 39.91 |
| Mar 2023 | 43,886 | 11,650 | 27.00 | 8,513 | 35.32 |
| Mar 2022 | 38,654 | 10,258 | 27.00 | 3,389 | 13.64 |
| Mar 2021 | 33,498 | 8,470 | 25.00 | 2,272 | 12.10 |
| Mar 2020 | 32,838 | 6,983 | 21.00 | 4,172 | 15.69 |
| Mar 2019 | 29,066 | 6,377 | 22.00 | 3,208 | 11.11 |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales growth | +9.7% | +13.0% | +2.0% | +15.4% | +13.5% | +10.5% | +8.4% | +11.2% |
| Operating profit growth | +13.2% | +9.5% | +21.3% | +21.1% | +13.6% | +11.7% | +16.1% | +17.3% |
| Net profit growth | +26.2% | +30.0% | -45.5% | +49.2% | +151.2% | +12.9% | +14.1% | +5.0% |
| EPS growth | +27.3% | +41.2% | -22.9% | +12.7% | +158.9% | +13.0% | +14.1% | +5.0% |
| OPM % | 22.0% | 21.0% | 25.0% | 27.0% | 27.0% | 27.0% | 29.0% | 30.0% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
Shareholding
AI Analysis
No AI analysis generated yet for Sun Pharmaceutical Industries.
Get Free AI Stock Analysis FREE →Latest News
-
Sun Pharmaceutical Industries Ltd drops for fifth straight session - Business Standard
-
Sun Pharmaceutical Industries consolidated net profit rises 27.04% in the June 2026 quarter - Business Standard
-
Sun Pharmaceutical Industries Ltd spurts 1.6%, up for five straight sessions - Business Standard
-
Sun Pharmaceutical Industries Shares Rise 2.03% in Today's Session - Moneycontrol.com
-
Sun Pharm moves up on getting nod to manufacture, market semaglutide in Brazil
-
Sun Pharma rises on getting nod to manufacture, market generic semaglutide in South Africa
-
Sun Pharma gets nod to manufacture, market generic semaglutide in South Africa
-
Sun Pharmaceutical Industries - Sun Pharma among 4 stocks to hit 52-week highs & rally up to 25% in a month - The Economic Times
-
Sun Pharmaceutical Industries Base Case Target Achieved
-
Sun Pharmaceutical Industries - Torrent Pharma among 6 stocks to hit 52-week highs & rally up to 25% in a month - The Economic Times
Frequently Asked Questions
What is the share price of Sun Pharmaceutical Industries today?
Sun Pharmaceutical Industries shares were last quoted at ₹1,760.00 (+0.0% on the day). Use the Refresh price button on this page for the latest available price. Prices are for information only.
What is the P/E ratio of Sun Pharmaceutical Industries?
Sun Pharmaceutical Industries has a price-to-earnings (P/E) ratio of 36.77 and a price-to-book (P/B) ratio of 5.15. The industry P/E is 53.33.
What is the 52-week high and low of Sun Pharmaceutical Industries?
The 52-week high of Sun Pharmaceutical Industries is ₹2,047.55 and the 52-week low is ₹1,547.25.
What is the market cap of Sun Pharmaceutical Industries?
The market capitalisation of Sun Pharmaceutical Industries is about ₹444,716.74 crore.
How did Sun Pharmaceutical Industries perform in its latest quarterly results?
In the latest quarter (Jun 2026), Sun Pharmaceutical Industries reported sales of ₹15,300.00 crore (+10.5%) and net profit of ₹2,901.00 crore (+26.5%), compared with the same quarter last year.
Is Sun Pharmaceutical Industries a good stock to buy?
This page is for information and is not investment advice. As per the data shown here, Sun Pharmaceutical Industries has a 3-year ROE of 16.00%, 3-year profit growth of 13.00%. Review the fundamentals, quarterly results and AI analysis on StockSpin, and consult a SEBI-registered adviser before investing.
What is the promoter holding in Sun Pharmaceutical Industries?
Promoters hold about 54.48% of Sun Pharmaceutical Industries.
Which sector does Sun Pharmaceutical Industries belong to?
Sun Pharmaceutical Industries belongs to the Pharmaceuticals & Drugs sector.